Collectively these data suggest that PIs have superior abilities to inhibit ERα/HER2 cross-talk pathways and thereby to suppress the growth of breast cancer cells compared to fulvestrant plus lapatinib. This evidence concerns the gene ESR1 and breast carcinoma.